Development asset linked to Abbott Pathology in public FDA and regional records.
pharma · Female Infertility · Breast Feeding
Abbott Pathology
Abbott Australasia Pty Ltd
Abbott Pathology drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Mile End, AU HQ
2001 Founded
41 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Mile End, AU
- Founded
- 2001
- Employees
- 41
- Programs
- 6
- Drugs
- 9
- Patents
- 0
Abbott Pathology pipeline
Portfolio lens on 9 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Abbott Pathology drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Abbott Pathology in public FDA and regional records.
-
Development asset linked to Abbott Pathology in public FDA and regional records.
-
Development asset linked to Abbott Pathology in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
ritonavir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Cytochrome P450 3A.
- Target
- Cytochrome P450 3A
- Mechanism
- Cytochrome P450 3A inhibitor
-
Development asset linked to Abbott Pathology in public FDA and regional records.